

# PRODUCT INFORMATION



## Prostratin

Item No. 10272

**CAS Registry No.:** 60857-08-1  
**Formal Name:** 9a-(acetyloxy)-  
1,1aR,1bS,4,4aR,7aS,7bR,8R,9,9aS-  
decahydro-4a,7b-dihydro-3-(hydroxymethyl)-  
1,1,6,8-tetramethyl-5H-cyclopropa[3,4]  
benz[1,2-e]azulen-5-one

**Synonyms:** 13-O-Acetylphorbol, NSC 623310, SA 101A

**MF:** C<sub>22</sub>H<sub>30</sub>O<sub>6</sub>

**FW:** 390.5


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 205, 235 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥1 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Prostratin is supplied as a crystalline solid. A stock solution may be made by dissolving the prostratin in the solvent of choice, which should be purged with an inert gas. Prostratin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of prostratin in these solvents is approximately 10 mg/ml.

### Description

Activation of latent reservoirs of HIV-infected cells is a treatment strategy designed to reduce viral load and eliminate the perpetuation of retroviral infection. Prostratin is a non-tumor promoting phorbol ester that potently induces HIV-1 reactivation in latent reservoirs of infected Jurkat-LAT-GFP cells with an IC<sub>50</sub> value of ~0.5 μM.<sup>1</sup> Originally, prostratin was isolated from plant sources including *P. prostrata*, *E. cornigera*, and *H. nutans*.<sup>2</sup> The effects of prostratin are mediated through activation of NF-κB via protein kinase C and by downregulation of HIV-1 receptor CD4 expression and its co-receptors CXCR4 and CCR5.<sup>3-5</sup>

### References

1. Bedoya, L.M., Márquez, N., Martínez, N., *et al. Biochem Pharmacol.* **77**, 965-978 (2009).
2. Wender, P.A., Kee, J.-M., and Warrington, J.M. *Science* **320**, 649-652 (2008).
3. Williams, S.A., Chen, L.-F., Kwon, H., *et al. J. Biol. Chem.* **279(40)**, 42008-42017 (2004).
4. Biancotto, A., Grivel, J.-C., Gondois-Rey, F., *et al. J. Virol.* **78(19)**, 10507-10515 (2004).
5. Hezareh, M., Moukil, M.A., Szanto, I., *et al. Antivir. Chem. Chemother.* **15**, 207-222 (2004).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/04/2020

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM